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Abstract
Background: In the progression of acne vulgaris, the disruption of follicular epithelia by an over-growth of
Propionibacterium acnes (P. acnes) permits the bacteria to spread and become in contact with various skin and immune cells.
Methodology/Principal Findings: We have demonstrated in the present study that the Christie, Atkins, Munch-Peterson
(CAMP) factor of P. acnes is a secretory protein with co-hemolytic activity with sphingomyelinase that can confer cytotoxicity
to HaCaT keratinocytes and RAW264.7 macrophages. The CAMP factor from bacteria and acid sphingomyelinase (ASMase)
from the host cells were simultaneously present in the culture supernatant only when the cells were co-cultured with P.
acnes. Either anti-CAMP factor serum or desipramine, a selective ASMase inhibitor, significantly abrogated the P. acnes-
induced cell death of HaCaT and RAW264.7 cells. Intradermal injection of ICR mouse ears with live P. acnes induced
considerable ear inflammation, macrophage infiltration, and an increase in cellular soluble ASMase. Suppression of ASMase
by systemic treatment with desipramine significantly reduced inflammatory reaction induced by intradermal injection with
P. acnes, suggesting the contribution of host ASMase in P. acnes-induced inflammatory reaction in vivo. Vaccination of mice
with CAMP factor elicited a protective immunity against P. acnes-induced ear inflammation, indicating the involvement of
CAMP factor in P. acnes-induced inflammation. Most notably, suppression of both bacterial CAMP factor and host ASMase
using vaccination and specific antibody injection, respectively, cooperatively alleviated P. acnes-induced inflammation.
Conclusions/Significance: These findings envision a novel infectious mechanism by which P. acnes CAMP factor may hijack
host ASMase to amplify bacterial virulence to degrade and invade host cells. This work has identified both CAMP factor and
ASMase as potential molecular targets for the development of drugs and vaccines against acne vulgaris.
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Introduction
Propionibacterium acnes (P. acnes), a Gram-positive, anaerobic and
lipophilic bacterium, plays an important role in inflammatory acne
vulgaris. This disease is the most common disorder of the human
skin, afflicting up to 80% of individuals at some point in their lives.
Over-proliferation of P. acnes can be found in the microcomedone,
which is the precursor of acne vulgaris characterized by
hyperkeratinization, formation of a keratin plug, and increase in
sebum secretion by the sebaceous gland [1–4]. The initial event in
the inflammation of severe acne is the disruption of follicular
epithelium by this overgrowth of P. acnes, allowing the bacteria in
the microcomedone to spread in contact with various skin and
immune cells such as keratinocytes and macrophages, thereby
triggering granulomatous reactions of inflammatory acne [5–7]. P.
acnes stimulates the production of pro-inflammatory cytokines,
including interleukins -1b, -8, -12, and tumor necrosis factor-a, via
toll-like receptor 2 [8–10].
Hemolysis has been employed by numerous bacterial pathogens
to degrade, invade host cells, and to resist the host immune attack.
This is achieved through various mechanisms such as enzymatic
and/or pore formation activities targeting the host cell membranes
[11]. When P. acnes is grown on a sheep blood agar plate in close
proximity to b-hemolytic microorganisms, such as Staphylococcus
aureus (S. aureus) and Clostridium perfringens [12], it synergistically
enhances hemolysis similar to the classical Christie, Atkins,
Munch-Peterson (CAMP) reactions first described by Christie
and co-authors [13]. The CAMP reactions occur in various
bacterial interactions. For example, in Streptococcus agalactiae (also
named as group B streptococci, GBS) and Bartonella henselae (B.
henselae), CAMP reactions are induced by the combination of
CAMP factor co-hemolysin, which is a secreted pore-forming
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partners such as S. aureus [14,15]. GBS CAMP factor itself has
weak hemolytic activity on the erythrocytes, but pre-treating the
cells with SMase enhances it’s activity [14]. S. aureus SMase
hydrolyzes sphingomyelin on the erythrocyte membranes to
ceramide, which renders the cells more susceptible to the
hemolytic activity of GBS CAMP factor [14]. The entire genomic
sequence of P. acnes includes numerous genes whose products are
involved in degrading host molecules [16–18]. Particularly, P. acnes
carries five genes encoding CAMP factor homologs [19]. One of
the CAMP factor homologs (CAMP factor 2, accession number:
gi/50842175) shows high identity (33%) in amino acid sequence to
the GBS CAMP factor.
Due to its co-hemolytic activity on erythrocytes in vitro, CAMP
factor has been proposed as a virulence factor for various
pathogens including GBS, Streptococcus uberis and B. henselae
[14,15,20,21]. However, the significance of erythrocyte lysis by
the CAMP reaction in vivo remains unclear and the cytotoxic
effects of CAMP factor on other cell types are not examined. In
addition to its co-hemolytic activity, GBS CAMP factor was
reported to bind to the Fc region of immunoglobulins G (IgG) and
M in a manner similar to Protein A of S. aureus, resulting in the
alternative nomenclature, Protein B [22]. However, some recent
evidence contradicted this observation [23]. Hensler and co-
workers demonstrated that full virulence was retained in a CAMP
factor knockout GBS mutant strain [24]. Therefore, the
involvement of CAMP factor co-hemolysin in the virulence of
pathogens remains controversial and not clear.
So far no bacterial source of SMases has been found in acne
lesions. Staphylococcus epidermidis is one of the major bacteria isolated
from acne lesions besides P. acnes, but it does not generate a CAMP
reaction with P. acnes (data not shown). On the other hand, S.
aureus expressing SMase can be found on the skin and is frequently
involved in cutaneous infections [25], but is rarely found in acne
lesions [26]. These facts suggest that the CAMP reaction between
P. acnes CAMP factor and other bacterial SMases may be
insignificant for the virulence of P. acnes. However, SMases have
been widely isolated and characterized from bacteria, yeast and
various tissues as well as biological fluids of mammals [27]. In spite
of low identity between bacterial and mammalian SMases, the
amino acid sequences share a number of conserved residues,
suggesting a common catalytic mechanism [28,29]. Here we
hypothesize that P. acnes benefits from a host SMase that amplifies
the CAMP factor-mediated virulence of P. acnes. To test this
hypothesis, we studied the involvement of a host SMase in CAMP
factor-mediated virulence of P. acnes both in vitro and in vivo.
Results
Recombinant CAMP Factor of P. acnes Is Biologically
Active and Displays a CAMP Reaction
To express the CAMP factor, E. coli competent cells
transformed with an expression plasmid containing an insert
encoding P. acnes CAMP factor were incubated with Isopropyl-b-
D-thiogalactoside (IPTG). A protein band with 32.4 kDa corre-
sponding to the molecular mass of CAMP factor plus a 66NH
fusion protein was detected in the insoluble fraction of IPTG-
induced E. coli (Figure 1A, left panel). A purified CAMP factor was
obtained by using a TALON resin column (Figure 1A, lane 3) and
sequenced by a NanoLC-LTQ MS/MS mass spectrometer after
in-gel trypsin digestion (Figure 1B). Nine peptides were fully
sequenced and matched well with internal amino acids of P. acnes
CAMP factor (accession number: gi/50842175) (data not shown).
A sequenced peptide (AVLLTANPASTAK; 147–158 amino acid
residues) of CAMP factor is presented (Figure 1B), validating the
expression and purification of recombinant CAMP factor. A
conventional CAMP reaction was utilized to examine the
biological activity of the recombinant CAMP factor. As shown
in Figure 1C, a co-hemolysis was observed when recombinant
CAMP factor was spotted adjacent to the SMase-expressing S.
aureus on a sheep blood agar plate. Because P. acnes carries five
genes encoding CAMP factor homologs [19], we examined co-
hemolysis activity of another CAMP factor homolog (CAMP
factor 4, accession number: gi/50840313), which shares high
amino acid sequence identity (29%)to the GBS CAMP factor,
however no activity was observed (Figure S1, Text S1). Other
CAMP factor homologs (1, 3 and 5) show lower identity in amino
acid sequences to the GBS CAMP factor. Thus, CAMP factor
homolog 2 was used for this study.
CAMP Factor Is Immunogenic When Mice Are Immunized
with E. coli Over-Expressing CAMP Factor
To examine the immunogenicity of CAMP factor, we
immunized ICR mice intranasally with UV-inactivated E. coli
over-expressing CAMP factor or green fluorescence protein (GFP)
(a control protein). Antibody (IgG) to CAMP factor was detected
14 days after immunization by a Western blot analysis (Figure 1D).
The immunoreactivity to CAMP factor was undetectable in the
GFP-immunized mice. ELISA analysis showed a significant
increase in antibody titers 14 and 21 days after immunization
(Figure 1E). Twenty-one days after immunization, the titer of anti-
CAMP factor IgG in the serum from the CAMP factor-immunized
mice was greater than 100,000 while the titer from the GFP-
immunized mice was less than 100.
P. acnes CAMP Factor Is a Secretory Protein
The supernatant of P. acnes cultures from logarithmic growth
phase was concentrated and subjected to Western blotting with
antiserum obtained from mice immunized with UV-inactivated E.
coli over-expressing CAMP factor or GFP. In the immunoreaction
to anti-CAMP factor antiserum, we detected a single band
(Figure 1F, left panel, lane 2) at the position corresponding to
recombinant CAMP factor that had been treated with enteroki-
nase to remove 66NH tag (Figure 1F, left panel, lane 1). The band
was undetectable in the concentrated Reinforced Clostridium
Medium (RCM) that was used for P. acnes culture (Figure 1F, left
panel, lane 3). As a contrast, no bands were detected when the
supernatant of P. acnes cultures was immunoreacted to anti-GFP
antiserum (Figure 1F, right panel).
CAMP Factor Is Cytotoxic to Keratinocytes and
Macrophages
In the event of granulomatous type of severe acne inflamma-
tion, P. acnes escapes from the ruptured follicular wall and
interacts with various skin cells such as keratinocytes and
phagocytic cells such as macrophages. To explore the cytotoxicity
of CAMP factor, a human HaCaT keratinocyte cell line and a
murine RAW264.7 macrophage cell line were treated with
various concentrations of recombinant CAMP factor or GFP. It
was found that the treatment with CAMP factor resulted in dose-
dependent cytotoxicity in both HaCaT and RAW264.7 cells
(Figure 2A). To examine the virulence of P. acnes CAMP factor in
vivo, mouse ear was injected intradermally with recombinant
CAMP factor or GFP. Injection of CAMP factor, but not GFP,
for 24 hr induced a significant increase in ear thickness
(Figure 2B), demonstrating the virulence of P. acnes CAMP factor
in an inflammatory reaction.
P.acnes CAMP Factor and ASMase
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acnes Virulence
To examine whether acid SMase (ASMase) is released from host
cells in the presence of P. acnes, HaCaT and RAW264.7 cells were
cultured with or without P. acnes for 14 hr, respectively. After
incubation, the culture supernatant was subjected to Western
blotting, probing with an anti-CAMP factor antiserum and an
anti-ASMase IgG. The CAMP factor and ASMase were
simultaneously present in the culture supernatant only when the
cells were co-cultured with P. acnes (Figure 3A, lanes 1 and 2). The
human (gi/179095) and mouse (gi/21961231) mature ASMases
with similar molecular weights share greater than 90% amino acid
identity [30]. Neither of these ASMases was detected in the culture
supernatant in the absence of P. acnes (Figure 3A, lanes 3 and 4).
Furthermore, the ASMase was not detectable in the supernatant of
P. acnes culture alone (data not shown). These findings indicate that
both CAMP factor and ASMase are released when co-culturing P.
acnes with host cells.
To examine the effect of neutralization of CAMP factor on P.
acnes-induced cytotoxicity, HaCaT and RAW264.7 cells were co-
cultured with P. acnes in the presence of anti-CAMP factor or
anti-GFP antiserum. As shown in Figure 3B, in the presence of
anti-GFP antiserum, P. acnes induced 29.363.8% and
44.063.4% cell death on HaCaT and RAW264.7 cells,
respectively. The co-culture of anti-CAMP factor antiserum
reduced P. acnes-induced cell death of HaCaT and RAW264.7
cells to 18.263.9% and 2.164.6%, respectively. To investigate
the involvement of host ASMase in the cytotoxicity of P. acnes,
cells were co-cultured with P. acnes in the presence of
desipramine, a selective ASMase inhibitor, or an equal volume
Figure 1. Characterization of P. acnes CAMP factor. (A) Recombinant CAMP factor (arrowheads) of P. acnes was expressed in E. coli. The protein
expression was incubated without (lane 1) or with (lane 2) IPTG. Purified recombinant CAMP factor is shown (lane 3). (B) The identity of recombinant
CAMP factor was analyzed by NanoLC-LTQ MS/MS mass spectrometry. A sequenced internal peptide (AVLLTANPASTAK) of CAMP factor is presented.
(C) Co-hemolytic activity of recombinant CAMP factor was examined on a sheep blood agar plate. Recombinant CAMP factor (2.5 mg) or a GFP control
protein (2.5 mg) was spotted beside the S. aureus streak. (D) Immunogenicity of CAMP factor was evaluated by Western blotting. ICR mice were
intranasally vaccinated with UV-inactivated E. coli over-expressing CAMP factor or GFP. Sera were collected 14 days after the vaccination. Anti-CAMP
factor (1:2,000 dilution; lanes 1 and 2) or anti-GFP antiserum (lanes 3 and 4) was reacted with recombinant CAMP factor (0.2 mg; lanes 1 and 3) or GFP
(lanes 2 and 4). (E) The antibody titer of CAMP factor was quantified by ELISA. The antisera (1:10,000 dilution) were reacted with purified recombinant
CAMP factor immobilized on a microtiter ELISA plate. The captured antibodies were detected by an OptEIA
TM Reagent Set consisting of a goat-anti-
mouse IgG (H+L)-HRP conjugate. The OD of each well was measured at 450 nm. Horizontal bar represents average of 10 individual assays. (F) CAMP
factor was detectable in P. acnes culture medium by Western blotting. Recombinant CAMP factor (0.2 mg; lane 1) as a positive control, P. acnes culture
medium (70 mg; lane 2), and RCM (70 mg; lane 3) as a negative control were reacted with mouse anti-CAMP factor antiserum (1:1,000 dilution, left
panel) or anti-GFP antiserum (right panel). The 66HN tag linked to recombinant CAMP factor was removed by enterokinase before loading into a
SDS-PAGE.
doi:10.1371/journal.pone.0014797.g001
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43.461.4% and 45.461.8% cell death on HaCaT and
RAW264.7 cells, respectively. The addition of desipramine
significantly reduced P. acnes-induced cell death on both cells to
21.963.2% and 30.662.7%, respectively. These results clearly
show that both bacterial CAMP factor and cell ASMase are part
of the cause of cytotoxicity induced by P. acnes.
To assess the contribution of host ASMase in P. acnes cytotoxicity
in vivo, the ears of ICR mice wereinjected intradermallywithP. acnes
or PBS for 24 hr and subsequently excised for the following studies.
First, the supernatant of ear homogenate was immunoreacted to
anti-ASMase IgG in a Western blot analysis (Figure 4A). A single
band corresponding to ASMase with a molecular weight of about
60 kDa was detected. P. acnes injection significantly increased the
amount of soluble ASMase in the ear in comparison with PBS
injection. Second, frozen sections of mouse ears were stained with
anti-mouse CD11b IgG (red), a macrophage positive marker,
followed by anti-ASMase IgG (green) (Figure 4B). The merged
images (pink) evidently illustrated that ASMase was predominantly
expressed in the infiltrating CD11b
+ macrophages, suggesting that
injection of P. acnes, but not PBS, recruited the infiltration of
macrophages. Third, transmission electron microscopy showed that
P. acnes was phagocytosed in macrophage-like cells as well as
distributed in the extracellular space 24 hr after bacterial injection
(Figure 4C). Furthermore, ruptured cell membranes were observed
exclusively in the P. acnes-, but not PBS-injected ears, indicating that
intradermal P. acnes injection induces the infiltration of ASMase-
expressed macrophages. Lastly, measurement of ear thickness
showed that P. acnes-induced ear swelling was significantly alleviated
when mice were pretreated systemically with desipramine for
30 min (Figure 4D), supporting that host ASMase engages P. acnes-
induced ear inflammation. All these findings concurrently demon-
strate the co-contribution of CAMP factor and ASMase to P. acnes
virulence in terms of cytotoxicity and inflammation.
Figure 2. Virulence of P. acnes CAMP factor. (A) Cytotoxicity of recombinant CAMP factor was examined using HaCaT and RAW264.7 cells. The
cells were incubated with recombinant CAMP factor or GFP at the indicated concentrations at 37uC for 18 hr. After the incubation, cytotoxicity was
measured as described in Experimental Procedures. The data represent mean 6 standard error (SE) (n=6,p,0.005** and p,0.0005*** by Student’s t-
test, CAMP factor vs. GFP control). (B) Intradermal injection with CAMP factor induced the ear thickness increase of ICR mice. The left ear was
intradermally injected with 20 ml of recombinant CAMP factor (10 mg) or GFP (10 mg) in PBS. Right ear received an equal volume of PBS. The ear
thickness was measured using a micro caliper 24 hr after the injection and normalized to that of the PBS-injected ears. The data represented as mean
6 SE (n=4,p,0.005** by Student’s t-test).
doi:10.1371/journal.pone.0014797.g002
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ASMase Cooperatively Suppress P. acnes-Induced
Inflammation
ICR mice were vaccinated intranasally with UV-inactivated E.
coli over-expressing CAMP factor or GFP. P. acnes or PBS was
injected intradermally into the ears of vaccinated mice for 24 hr.
Thirty minutes after bacterial injection, the left ear, which
received P. acnes, was subsequently injected with anti-ASMase
IgG or normal goat IgG, while the right ear, which received
PBS, was continuously injected with an equal volume of PBS. In
comparison with increased ear thickness in the mice treated with
GFP vaccination combined with normal IgG injection, P. acnes-
induced ear swelling was reduced for the combination of GFP
vaccination with anti-ASMase IgG injection (20.762.9% inhibi-
tion) and the combination of CAMP factor vaccination with
normal goat IgG (25.861.9% inhibition). More importantly, the
combination of CAMP factor vaccination with anti-ASMase IgG
injection reduced P. acnes-induced ear swelling (60.363.9%
inhibition) (Figure 5). This result demonstrates that a synergistic
abrogation of P. acnes-induced inflammation may occur when
both P. acnes CAMP factor and host ASMase are suppressed.
The result also suggests a cross-talk between P. acnes CAMP
Figure 3. Synergy of P. acnes’ CAMP factor with a cellular ASMase in promoting cytotoxicity. (A) CAMP factor and ASMase were
detectable by Western blotting in the medium of co-culturing P. acnes and the cells. The HaCaT (lanes 1 and 3) or RAW264.7 (lanes 2 and 4) cells were
cultured together with P. acnes (MOI=1:10) (lanes 1 and 2) or without P. acnes (lanes 3 and 4) in a serum-free medium at 37uC for 14 hr. CAMP factor
and ASMase secreted into the culture media were detected by mouse anti-CAMP factor antiserum and goat anti-ASMase IgG, respectively. (B) P.
acnes-mediated cytotoxicity was neutralized by anti-CMAP factor antiserum in vitro. HaCaT or RAW264.7 cells were co-cultured with P. acnes
(MOI=1:10) for 14 hr in the presence of mouse anti-CAMP factor or anti-GFP antiserum (2.5% v/v). (C) ASMase inhibitor suppressed P. acnes-mediated
cytotoxicity in vitro. HaCaT or RAW264.7 cells were cultured without or with P. acnes (MOI=1:10) in medium containing desipramine (10 mM), a
selective ASMase inhibitor, or the equal volume of PBS at 37uC for 14 hr. After incubation, cytotoxicity was calculated as described in Experimental
Procedures. The data represent as mean 6 SE (n=10, p,0.05* and p,0.0005*** by Student’s t-test).
doi:10.1371/journal.pone.0014797.g003
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virulence.
Discussion
The hemolysis mainly caused by hemolysins is thought to be a
virulence activity of numerous microbial pathogens to degrade
tissues, invade host cells, disseminate themselves, and escape from
the host immune attack. Microbial hemolysins generally possess
the capability to lyse erythrocytes in vitro, but many of them are
toxic to other cell types as well [11]. We observed that P. acnes
secretes CAMP factor as an exotoxin (Figure 1F). Although the
hemolytic action of bacterial CAMP factor has been demonstrated
on erythrocytes and artificial plasma membranes [14,15,31], little
attention has been paid to the cytotoxicity of CAMP factor on
other cell types. Here, we examined cytotoxic activity of P. acnes
CAMP factor on host cells, and its physiologic relevance to the
pathogenicity of P. acnes, which is highly relevant to severe
inflammatory acne vulgaris. In the case of severe acne vulgaris, the
keratinocytes and macrophages are two major target cells when P.
acnes escapes from ruptured follicular wall. Our data demonstrated
that P. acnes CAMP factor is toxic to both human HaCaT
keratinocytes and murine RAW264.7 macrophages (Figure 2A).
However, we could not conclude that CAMP factor itself exerts
cytotoxic effects on these cells as they have ASMase (Figure 3).
Synergistic effect of recombinant CAMP factor and cellular
ASMase might be involved in the dose-dependent cytotoxic effect.
There have been only a few studies showing that CAMP factor is a
potential virulence factor of pathogen in vivo. A high dose of
partially purified CAMP factor from GBS was lethal to rabbits and
mice when it was injected intravenously [32]. Mice that had been
infected with sublethal doses of GBS developed fatal septicemia
after receiving repeated injections with purified CAMP factor [22].
We demonstrated that intradermal injection of the mouse ears
with recombinant CAMP factor of P. acnes induced ear swelling
(Figure 2B), indicating that CAMP factor is involved in P. acnes-
induced inflammation in vivo. Furthermore, we demonstrated that
intradermal injection of mouse ears with live P. acnes induces
tremendous infiltration of ASMase-expressed CD11b
+ macro-
phages (Figure 4B and C), consistent with our previous observation
that injection of live P. acnes into an implanted tissue chamber-
imitated acne microenvironment recruited remarkable CD11b
+
macrophages [33].
Several different forms of mammalian SMases have been
identified, including soluble endosomal/lysosomal SMase present
in all mammalian tissues, plasma membrane-associated neutral
SMase predominantly present in the central nervous system, and
cytosolic SMase [34–37]. These enzymes catalyze the hydrolytic
cleavage of sphingomyelin on the cell membrane to ceramide in
the same catalytic mechanism as bacterial SMases. The released
ceramide, in turn, can act as a cellular signal to trigger various
activities such as apoptosis, differentiation, and proliferation [38].
The activity of the SMases are regulated by a wide range of
extracellular signaling; growth factors, cytokines, neurotransmit-
ters, hormones, and stresses, such as ultraviolet and reactive
oxygen species [35]. Ubiquitously-expressed ASMase exerts
important functions during the innate immune response to
infectious pathogens [39]. Therefore, we focused on the
interaction of host ASMase and bacterial CAMP factor as related
to virulence of P. acnes. ASMase was released from the host cells
when exposing to P. acnes (Figure 3A). The cytotoxicity of P. acnes
was dramatically neutralized in the presence of mouse anti-CAMP
factor antiserum or a specific ASMase inhibitor, desipramine [40],
(Figure 3B and C), suggesting that P. acnes CAMP factor and cell
ASMase co-contribute to the virulence of P. acnes. However, anti-
Figure 5. Combination of CAMP factor vaccination and
intradermal injection with anti-ASMase IgG cooperatively
suppressed P. acnes-induced ear inflammation. ICR mice were
vaccinated with UV-inactivated E. coli over-expressing CAMP factor
(solid and grey bars) or GFP (hatched and open bars) in a 3-week
interval. Two weeks after the second boost, P. acnes was injected
intradermally into the ears of vaccinated mice in the same manner as
described in Figure 4. Thirty min after bacterial injection, ears at the
same site received P. acnes (left ear) or PBS (right ear) were
subsequently injected with goat anti-ASMase IgG (4 mg) (n=8). As a
control, an equal volume of normal goat IgG in PBS was injected
intradermally into both ears (n=8). The change in ear thickness was
measured 24 hr after the bacterial injection and normalized to that of
the PBS-injected ears. The data was expressed as percent inhibition of P.
acnes-induced increase in ear thickness determined by comparison with
that in the mice treated with GFP vaccination combined with normal
IgG injection. The data represent as mean 6 SE (p,0.05*, p,0.005**,
p,0.0005*** by Student’s t-test).
doi:10.1371/journal.pone.0014797.g005
Figure 4. Involvement of host ASMase in the virulence of P. acnes in vivo. (A) The level of soluble ASMase in mouse ear was elevated 24 hr
after bacterial injection. Ears of ICR mice were injected intradermally with P. acnes (1610
7 CFU; left ear) or PBS (right ear) for 24 hr. Ear tissues were
homogenized in PBS and centrifuged. The supernatant (1 mg) was subjected to Western blotting using anti-ASMase IgG and anti-GAPDH IgG. Normal
goat and mouse IgG were used as negative controls. (B) P. acnes injected into mouse ear recruited CD11b
+ macrophages that highly expressed
ASMase. Frozen sections of mouse ears obtained 24 hr after bacterial injection were stained with biotinylated anti-mouse CD11b IgG, a conventional
macrophage marker, and TRITC-streptavidin conjugate (red), followed by goat anti-ASMase IgG and anti-goat IgG-TRITC conjugate (green).
Biotinylated normal mouse IgG and normal goat IgG were used as isotype control antibodies. The nuclei were stained with DAPI (blue). Broken lines
represent the outlines of ear sections. Bar=200 mm. (C) Transmission electron microscopy (10,0006magnification) was utilized to visualize colonized
P. acnes and ruptured cell membranes in mouse ears injected with P. acnes or PBS. PA, P. acnes; CM, cell membrane; NC, nucleus. Bar=1 mm. (D)
Systemic pre-treatment of ICR mice with a selective ASMase inhibitor alleviated P. acnes-induced increase in ear thickness. ICR mice were injected
intraperitoneally with desipramine (20 mg/kg mouse) (solid bars) or an equal volume of PBS (open bars) 30 min prior to bacterial injection. Live P.
acnes (1610
7 CFU) and an equal volume of PBS were injected intradermally into left ear and right ear of the mice, respectively. The ear thickness was
measured before and 24 hr after bacterial injection, and was normalized to that of the PBS-injected controls. The data represent as mean 6 SE (n=3,
p,0.005** by Student’s t-test).
doi:10.1371/journal.pone.0014797.g004
P.acnes CAMP Factor and ASMase
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of P. acnes on HaCaT cells, suggesting that there are other
cytotoxic mechanisms in addition to the CAMP factor for
keratinocytes. Because desipramine displays an anti-depressant
property as well as anti-ASMase inhibition [41,42], we examined
the specificity of desipramine on CAMP factor-mediated cytotox-
icity. Desipramine significantly suppressed the cytotoxicity of P.
acnes CAMP factor, but did not influence the cytotoxicity
associated with S. aureus a-toxin, used as a control toxin (Figure
S2, Text S1). The data also indicates that host ASMase is
specifically involved in virulence of P. acnes CAMP factor, but not
in those of other toxins. In addition, desipramine may have a
therapeutic potential for acne by blocking the synergistic
cytotoxicity of P. acnes CAMP factor and host ASMase.
Inhibition of both P. acnes CAMP factor and host ASMase
synergistically suppressed the P. acnes-induced inflammation
(Figure 5), indicating a cross-talk between CAMP factor and
ASMase. These data suggest an opportunity to block the cross-talk
as an anti-inflammatory treatment of acne. To our knowledge, this
may be the first study to examine the therapeutic potential of
blocking CAMP factor as a treatment of infection. In future
experiments, however, it will be necessary to investigate whether
host ASMase enhances bacterial CAMP factor toxicity in vitro and
to use ASMase deficient mice and a CAMP factor-deficient
mutant of P. acnes to completely confirm the existence of cross-talk.
Lang and co-authors have reported that GBS CAMP factor
binds to glycosylphosphatidylinositol (GPI)-anchored proteins on
the cell membrane of erythrocytes, which act as cell surface
receptors for this toxin [31,43]. The interaction between the GBS
CAMP factor and the GPI-anchored proteins further induce the
formation of oligomeric pores in sheep erythrocyte membranes
[14]. The amount of GPI-anchored proteins is augmented by the
reduction of sphingolipid levels on the cell membrane [44]. Since
GPI-anchored proteins are found ubiquitously in mammalian cells
[45], the same mechanism may be involved in the cytotoxic
reaction of P. acnes CAMP factor to keratinocytes and macro-
phages. Indeed, removal of sphingomyelin on the cell membranes
by pre-treating the cells with bacterial SMase increased the cell
susceptibility to P. acnes CAMP factor (Figure S3, Text S1).
The contribution of host ASMase to P. acnes virulence was also
examined. Ears of ICR mice were injected intradermally with live
P. acnes [46,47]. The amount of soluble ASMase increased in the
ears after injection with P. acnes (Figure 4A). The model of
granulomatous reactions in mouse ears (Figure 4B and C)
recapitulates severe inflammatory acne in humans, in which
numerous P. acnes has been observed inside phagosomes of an
infiltrating macrophage [6]. It has been reported that P. acnes
resists killing by phagocytes and is able to survive in macrophages
[48]. GBS b-hemolysin/cytolysin, a pore-forming exotoxin, has
been demonstrated to contribute to the subversion of phagocytic
host immune defenses [49]. During the intracellular life cycle of
Listeria monocytogenes, a pore-forming toxin named listeriolysin O is
largely responsible for mediating phagosomal membrane rupture
to allow the pathogen escaping from the phagosome into the host
cytosol [50]. Lysosomal ASMase plays an important role in
macrophage killing bacteria at the early stage of phagocytosis
[51,52] and enables proper fusion of late phagosomes with
lysosomes, which is crucial for efficient transfer of lysosomal
antibacterial hydrolases into phagosomes [53]. The results in this
paper highlights the possibility that phagocytosed P. acnes in the
macrophage may take advantage of the host lysosomal ASMase to
enhance the toxicity of CAMP factor and thus escape from
phagosomes. This may also explain the possible mechanism of P.
acnes resistance against phagocytosis. Indeed, we observed a
number of macrophages in the P. acnes-injected ear, many of which
had cell membranes ruptured by colonizing P. acnes (Figure 4C). In
agreement with our observation in Figure 3A, infection by
Salmonella or E. coli triggered an early surge of the extracellular
secretion of ASMase from macrophages [51]. P. acnes may
shrewdly utilize the secreted ASMase from macrophages to escape
from the host cells and spread invasively from cell to cell. Our
results also envision that P. acnes CAMP factor hijacks host
ASMase to amplify its virulence.
We have recently developed acne vaccines using UV-killed P.
acnes [54] or a cell-wall anchored sialidase [55] as an antigen.
These vaccines will benefit patients with severe acne or other P.
acnes-associated diseases such as polymer (device)-associated
diseases, sepsis, toxic shock syndrome, endocarditis, osteomyelitis
and various surgery infections [56]. It has been reported that a
single intraperitoneal injection of phenol-treated P. acnes into mice
showed non-specific resistance against subsequent lethal doses of
an intraperitoneal challenge of S. aureus and Streptococcus pyogenes
[57]. This suggests that using killed P. acnes as a vaccine may lack
bacterial specificity. Instead, vaccines that target the secreted
virulence factors such as CAMP factor may work in a different way
from surface-targeted vaccines, thereby eliciting the bactericidal
antibodies to eradicate bacteria directly. Recently, it has been
demonstrated that inhibition of microbial secreted virulence
factors present less selective pressure for the generation of
resistance [58]. P. acnes is a ubiquitous commensal on the human
body and can become pathogenic in anaerobic acne lesions [59].
Since the P. acnes CAMP factor and host ASMase are secreted
locally in acne microenvironment, the application of vaccines that
target the secreted CAMP factor instead of other bacterial surface
proteins and antibodies that neutralize ASMase may be able to
locally suppress the P. acnes virulence while not killing the bacteria
or impacting the bacterial commensalism in other locations of the
body.
Materials and Methods
Ethics statement
All animal protocols were reviewed and approved by the
University of California San Diego (approval number: S09330)
and the Veterans Affairs San Diego Healthcare System subcom-
mittee on animal studies (approval number: 08-308).
Bacterial culture
P. acnes (ATCC 6919) was as described by our previous reports
[54,55,60]. S. aureus 113 (ATCC 35556) was cultured on Tryptic
soy broth (TSB) agar plates. Bacteria isolated from a single colony
were inoculated in TSB at 37uC overnight. Bacterial pellets were
harvested by centrifugation at 5,000 g for 10 min.
Molecular cloning and expression of recombinant CAMP
factor
A PCR product encoding a putative mature protein (29-267
amino acid residues) of CAMP factor (accession number: gi/
50842175) was generated by using P. acnes genomic DNA as a
template, the forward PCR primer (59-TAAGGCCTCTGTC-
GACGTCGAGCCGACGACGACCATCTCG-39) and the re-
verse PCR primer (59-CAGAATTCGCAAGCTTGGCAGCC-
TTCTTGACATCGGGGGAG-39). The amplified DNA prod-
ucts were inserted into the In-Fusion Ready pEcoli-Nterm 66HN
vector (Clontech Laboratories, Mountain View, CA) and trans-
formed into competent cells [Escherichia coli (E. coli), BL21 (DE3),
Invitrogen, Carlsbad, CA]. To express GFP, a pEcoli-Nterm-GFP
plasmid (Clontech Laboratories Inc.) was transformed. IPTG
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protein was purified in a denaturing condition with a TALON
Express Purification Kit (Clontech Laboratories Inc.). The purified
protein was refolded as described previously [55].
Protein identification via mass spectrometry (MS)
In-gel digestion with trypsin and protein identification via a
Nano liquid chromatography linear trap quadrupole mass
spectrometry (NanoLC-LTQ MS/MS) analysis were performed
as described previously [61].
Co-hemolytic activity of CAMP factor
Co-hemolytic reaction of recombinant CAMP factor was
detected on a sheep blood agar plate according to the previous
method [62] with minor modification. S. aureus 113 (ATCC 35556)
[10 ml, 2610
7 colony forming unit (CFU)/ml], used as a source of
SMase, was streaked on an agar plate. Recombinant CAMP factor
or GFP (2.5 mg) was spotted beside the S. aureus streak grown at
37uC for 18 hr.
Vaccination and titration of antibodies to CAMP factor
An 8-week-old female Institute Cancer Research (ICR) mouse
strain (Harlan, Indianapolis, IN) was used in all animal
experiments. ICR mice were housed according to institutional
guidelines. The mice were intranasally vaccinated with UV-
inactivated E. coli over-expressing CAMP factor or GFP. The use
of a UV-irradiated E. coli vector eliminates the necessity of
boosting [63].
To qualify the titer of antibody to CAMP factor, recombinant
CAMP factor (5 mg/ml) was coated onto a 96-well ELISA plate
(Corning, Lowell, MA). After blocking, antisera (1:10,000 dilution)
obtained from mice vaccinated with E. coli over-expressing CAMP
factor or GFP were added to the wells and incubated for 2 hr. A
goat anti-mouse IgG (H+L) IgG-horseradish peroxidase (HRP)
conjugate (Promega, Madison, WI) (1:5,000 dilution) was added
and incubated for 2 hr. HRP activity was determined with an
OptEIA
TM Reagent Set (BD Biosciences, San Jose, CA). The OD
of each well was measured at 450 nm.
Cell culture, cytotoxicity determination and
neutralization assay
A human keratinocyte cell line, HaCaT [64], and a murine
macrophage cell line, RAW264.7 (ATCC, Manassas, VA), was
cultured in DMEM and RPMI 1640 medium, respectively,
supplemented with 10% heat-inactivated fetal bovine serum
(FBS). For determination of the cytotoxicity of CAMP factor,
cells (1610
5/well) were incubated in a 96-well plate with
recombinant CAMP factor or GFP in a 1% FBS-medium for
18 hr. After incubation, cell viability was determined by an acid
phosphatase (ACP) assay [65] as described previously [54,55]. The
cytotoxicity of recombinant proteins was calculated as the
percentage of cell death caused by Triton X-100 (0.1%, v/v).
To detect the release of CAMP factor and acid SMase
(ASMase), HaCaT or RAW264.7 cells (5610
5/well) were co-
cultured with or without P. acnes [5610
6 CFU/well; multiplicity of
infection (MOI)=1:10] in a serum-free medium in a 24-well plate
at 37uC for 14 hr. After centrifugation, the supernatant was
filtrated with a 0.22 micro pore-size filter and then concentrated
10-fold using a 10 kDa cut-off ultrafiltration membrane (Amicon
Inc., Beverly, MA). The concentrated supernatant (10 mg) was
subjected to a 10% SDS-PAGE for Western blot analysis using
mouse anti-CAMP factor antiserum and goat anti-ASMase IgG
(Santa Cruz Biotechnology Inc., Santa Cruz, CA).
For neutralization assay, cells (1610
5/well) were co-cultured
with P. acnes (1610
6 CFU/well; MOI=1:10) for 14 hr in the
presence of anti-CAMP factor or anti-GFP antiserum (2.5%, v/v)
in which complements were deactivated by heating. To examine
the involvement of host ASMase in P. acnes virulence, cells were co-
cultured with P. acnes in the presence or absence of desipramine
(10 mM) (Sigma, St. Louis, MO), a cell-permeable selective
ASMase inhibitor [40], for 14 hr. After incubation, the cytotox-
icity of P. acnes was determined as described above.
Intradermal injection of mouse ears with recombinant
CAMP factor
Ears of ICR mice were injected intradermally with 20 mlo f
recombinant CAMP factor (0.5 mg/ml) or GFP in PBS. The
contralateral ear received an equal volume of PBS. The ear
thickness was measured using a micro caliper (Mitutoyo,
Kanagawa, Japan) 24 hr after injection. The increase in ear
thickness of CAMP factor- or GFP-injected ear was normalized to
that of the PBS-injected ears.
Detection of ASMase in mouse ears
Ears of ICR mice were injected intradermally with live P. acnes
(1610
7 CFU/20 ml in PBS). The contralateral ear received an
equal volume of PBS. Twenty four hr after bacterial injection, the
ear was excised, punched with an 8 mm biopsy and homogenized
in PBS. After centrifugation, the supernatant (1 mg) was subjected
to a Western blot analysis using goat anti-ASMase IgG (0.2 mg/ml)
(Santa Cruz Biotechnology, Inc.) followed by monoclonal anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) IgG (2 mg/
ml) (Fitzerald Inc., Concord, MA). Normal goat IgG or mouse IgG
was used as a negative control.
Transmission electron microscopy and fluorescence
immunohistochemistry
Mouse ears were injected intradermally with live P. acnes or PBS
as described above. Twenty four hr after bacterial injection, ears
were excised and fixed in Karnovsky’s fixative followed by 1%
OsO4 in 0.1 M Na Cacodylate buffer, pH 7.4. After polymeri-
zation with epoxy resin, thin sections were prepared. Sections were
examined at an accelerating voltage of 60 kV using a Zeiss
EM10C electron microscope (Oberkochen, Germany).
For fluorescence immunohistochemistry, the P. acnes-injected
ears were excised 24 hr after bacterial injection. Frozen sections
were fixed in 10% formamide. After blocking with PBS containing
5% BSA and anti-mouse cluster of differentiation (CD) 16/CD32
IgG (5 mg/ml) (BD Biosciences), sections were then incubated with
biotinylated anti-mouse CD11b IgG (5 mg/ml) (BD Biosciences), a
macrophage marker, followed by goat anti-ASMase IgG (5 mg/ml)
for 30 min. Biotinylated normal mouse IgG and normal goat IgG
were used as isotype control antibodies. After that, sections were
incubated with tetramethylrhodamine isothiocyanate (TRITC)-
streptavidin conjugate (5 mg/ml) (ZYMED, Carlsbad, CA) or
fluorescein isothiocyanate (FITC)-labeled anti-goat IgG (5 mg/ml)
(Santa Cruz Biotechnology Inc.) for 30 min at room temperature
before counterstaining with by 49-6-Diamidino-2-phenylindole
(DAPI) (Sigma).
Effect of desipramine on P. acnes-induced inflammation
in vivo
ICR mice were injected intraperitoneally with desipramine
(20 mg in PBS/kg mouse). Because 86% of desipramine binds to
plasma proteins [66], the dosage was determined to achieve a
higher plasma concentration (about 1 mM as the average total
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concentration used for in vivo assay (10 mM). Injection of an equal
volume of PBS serves as a control. Thirty minutes after
desipramine treatment, the ears were injected intradermally with
either live P. acnes or PBS. Ear thickness was measured before and
24 hr after bacterial injection, and was normalized to that of PBS-
injected ears.
Cooperative effects of CAMP factor-based vaccine and
anti-ASMase IgG on the suppression of P. acnes-induced
inflammation
ICR mice were vaccinated with inactivated E. coli over-
expressing CAMP factor or GFP in a 3-week interval. Two weeks
after the second boost, live P. acnes (1610
7 CFU/20 ml in PBS) was
injected intradermally into the left ears of vaccinated mice. The
same volume of PBS was injected into right ears of the same mice.
Thirty minutes after injection, both ears were subsequently
injected with goat anti-ASMase IgG (4 mg/20 ml) or normal goat
IgG as a negative control. The ear thickness in the left ears was
normalized to that of the PBS-injected right ears.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0014797.s001 (0.03 MB
DOC)
Figure S1 Co-hemolytic activity of recombinant CAMP factor
4. Co-hemolytic reaction of recombinant CAMP factor 4 was
examined on a sheep blood agar plate as described in Materials
and Methods. Recombinant CAMP factor 4 or GFP (2.5 mg) was
spotted beside the S. aureus streak grown at 37uC for 18 hr.
Found at: doi:10.1371/journal.pone.0014797.s002 (0.02 MB
PDF)
Figure S2 Desipramine suppressed cytotoxicity of P. acnes
CAMP factor but not S. aureus a-toxin. HaCaT cells were
incubated with CAMP factor (100 mg/ml), GFP (100 mg/ml), or
a-toxin (20 mg/ml) in 1% FBS-medium for 18 hr in the presence
or absence of desipramine (10 mM). After the incubation,
cytotoxicity was measured as described in Experimental Proce-
dures. The data represent mean 6 standard error (SE) (n=8,
p,0.05* and p,0.0005*** by Student’s t-test, desipramine vs.
vehicle control).
Found at: doi:10.1371/journal.pone.0014797.s003 (0.15 MB JPG)
Figure S3 Co-cytotoxic properties of CAMP factor and bacterial
SMase in vitro. The HaCaT or RAW264.7 cells were pre-treated
with S. aureus SMase (350 mU/ml) or an equal volume of PBS
(vehicle) for 15 min and then incubated with 25 mg/ml of
recombinant CAMP factor or GFP at 37uC for 18 hr. After the
incubation, cell viability expressed as % of cytotoxicity was
determined. The data are presented as mean 6 SE (n=6,
p,0.0005*** by Student’s t-test).
Found at: doi:10.1371/journal.pone.0014797.s004 (0.18 MB JPG)
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